Cas:13826-05-6 dodecyl-(2-hydroxyethyl)-dimethylazanium,perchlorate manufacturer & supplier

Chemical Name:dodecyl-(2-hydroxyethyl)-dimethylazanium,perchlorate

CAS.NO:13826-05-6

Synonyms:1-Dodecanaminium,N-(2-hydroxyethyl)-N,N-dimethyl-,perchlorate (1:1)

Molecular Formula:C₁₆H₃₆ClNO₅

Molecular Weight:357.91400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:94.50000

Exact Mass:357.22800

LogP:4.19030

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-Dodecanaminium,N-(2-hydroxyethyl)-N,N-dimethyl-,perchlorate (1:1) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Dodecanaminium,N-(2-hydroxyethyl)-N,N-dimethyl-,perchlorate (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Dodecanaminium,N-(2-hydroxyethyl)-N,N-dimethyl-,perchlorate (1:1) Use and application,1-Dodecanaminium,N-(2-hydroxyethyl)-N,N-dimethyl-,perchlorate (1:1) technical grade,usp/ep/jp grade.

Related News: ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. Benzamide, 2-hydroxy-N-[5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]- manufacturers Now that Alexion’s Soliris is in AstraZeneca’s hands, the drugmaker is counting on the C5 inhibitor to help push it toward billions in sales in just a few years. But a prominent drug pricing watchdog is raising a red flag over its costs for patients with a rare neuromuscular disorder. 2-Benzoyl-m-acetophenaetidid suppliers CDMOs closely work with companies who want to pursue upcoming innovations in medicines, help cope with shortcomings of internal lab-to-manufacturing scale-up. (S)-2-[(S)-2-(2-Benzyloxycarbonylamino-acetylamino)-3-hydroxy-propionylamino]-propionic acid methyl ester vendor & factory For category of products which involve fermentation technologies, incentive is 20 per cent of the approved sales price. The government has put a cap of Rs. 10 crore per product per annum for five years. This is a seven year scheme from 2023-24 going up to 2029-30.,In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021.